ProMIS Neurosciences, Inc. (PMN)
$8.29-4.27%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $11M
- Beta
- -0.22
- P/E (TTM)
- -0.49
- Short % float
- 28.46%
- Days to cover
- 7.1
- SI change
- -0.6%
- 1W
- -9.10%
- 1M
- -35.69%
- vs SPY 1W
- -8.96%
- vs SPY 1M
- -38.19%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 8
- VALUE
- 6
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-85.9%
REV YoY-
ROE-143.1%
EPS YoY-
ROA-74.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.49
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.53
P/FCF-
EV/EBITDA-0.49
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO7.85
ND/EBITDA-
BETA-0.22
Company news
FAQ
- What is LOPJLB’s current signal on PMN?
- LOPJLB’s latest quantitative signal on ProMIS Neurosciences, Inc. (PMN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PMN in?
- ProMIS Neurosciences, Inc. (PMN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ProMIS Neurosciences, Inc. (PMN) do?
- ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to iden…